Table 3 Age distribution of sacral malignant tumors
From: Epidemiological characteristics of 1385 primary sacral tumors in one institution in China
Histology | 0–10 | 11–20 | 21–30 | 31–40 | 41–50 | 51–60 | 61–70 | 71–80 | 81–90 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
Malignant tumors | 9(1.3%) | 54(7.5%) | 88(12.3%) | 96(13.4%) | 139(19.4%) | 151(21.1%) | 122(17.0%) | 52(7.3%) | 5(0.7%) | 716 |
Chordoma | 0(0) | 1(0.3%) | 17(5.4%) | 29(9.2%) | 58(18.4%) | 85(26.9%) | 82(25.9%) | 39(12.3%) | 5(1.6%) | 316 |
Chondrosarcoma | 0(0) | 5(6.8%) | 14(18.9%) | 16(21.6%) | 19(25.7%) | 16(21.6%) | 4(5.4%) | 0(0) | 0(0) | 74 |
Myeloma | 0(0) | 0(0) | 2(3.8%) | 7(13.2%) | 13(24.5%) | 13(24.5%) | 12(22.6%) | 6(11.3%) | 0(0) | 53 |
Malignant peripheral nerve sheath tumor | 1(2.1%) | 5(10.6%) | 10(21.3%) | 5(10.6%) | 11(23.4%) | 9(19.1%) | 5(10.6%) | 1(2.1%) | 0(0) | 47 |
Ewing sarcoma | 5(10.6%) | 19(40.4%) | 9(19.1%) | 9(19.1%) | 4(8.5%) | 1(2.1%) | 0(0) | 0(0) | 0(0) | 47 |
Osteosarcoma | 1(2.5%) | 15(37.5%) | 13(32.5%) | 5(12.5%) | 3(7.5%) | 3(7.5%) | 0(0) | 0(0) | 0(0) | 40 |
Lymphoma | 0(0) | 2(5.7%) | 4(11.4%) | 5(14.3%) | 9(25.7%) | 9(25.7%) | 4(11.4%) | 2(5.7%) | 0(0) | 35 |
Solitary fibrous tumor | 0(0) | 0(0) | 4(20%) | 5(25%) | 4(20%) | 2(10%) | 4(20%) | 1(5%) | 0(0) | 20 |
Undifferentiated pleomorphic sarcoma | 0(0) | 0(0) | 1(5.9%) | 2(11.8%) | 3(17.6%) | 5(29.4%) | 4(23.5%) | 2(11.8%) | 0(0) | 17 |
Malignant giant cell tumor | 0(0) | 2(11.8%) | 6(35.3%) | 4(23.5%) | 2(11.8%) | 2(11.8%) | 1(5.9%) | 0(0) | 0(0) | 17 |
Malignant teratoma | 0(0) | 0(0) | 2(18.2%) | 4(36.4%) | 1(9.1%) | 2(18.2%) | 2(18.2%) | 0(0) | 0(0) | 11 |
Liposarcoma | 0(0) | 0(0) | 0(0) | 2(20.0%) | 4(40.0%) | 1(10.0%) | 3(30.0%) | 0(0) | 0(0) | 10 |
Ependymoma | 0(0) | 0(0) | 1(25.0%) | 0(0) | 2(50.0%) | 0(0) | 0(0) | 1(25.0%) | 0(0) | 4 |
Angiosarcoma | 0(0) | 0(0) | 0(0) | 0(0) | 1(33.3%) | 2(67.7%) | 0(0) | 0(0) | 0(0) | 3 |
Fibrosarcoma | 0(0) | 1(33.3%) | 0(0) | 0(0) | 2(67.7%) | 0(0) | 0(0) | 0(0) | 0(0) | 3 |
Hemangioendothelima | 1(33.3%) | 0(0) | 0(0) | 1(33.3%) | 0(0) | 0(0) | 1(33.3%) | 0(0) | 0(0) | 3 |
Myelocytic sarcoma | 0(0) | 0(0) | 1(33.3%) | 2(67.7%) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 3 |
Yolk sac tumor | 1(33.3%) | 2(67.7%) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 3 |
Leiomyosarcoma | 0(0) | 0(0) | 1(50.0%) | 0(0) | 1(50.0%) | 0(0) | 0(0) | 0(0) | 0(0) | 2 |
Alveolar soft part sarcoma | 0(0) | 0(0) | 2(100.0%) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 2 |
Leukemia | 0(0) | 1(50.0%) | 0(0) | 0(0) | 1(50.0%) | 0(0) | 0(0) | 0(0) | 0(0) | 2 |
Epithelioid sarcoma | 0(0) | 1(100.0%) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 1 |
Granulocyte sarcoma | 0(0) | 0(0) | 0(0) | 0(0) | 1(100.0%) | 0(0) | 0(0) | 0(0) | 0(0) | 1 |
Myofibroblastic sarcoma | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 1(100.0%) | 0(0) | 0(0) | 0(0) | 1 |
Synovial sarcoma | 0(0) | 0(0) | 1(100.0%) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 1 |